Showing results (321-330 of 457) with videos related to
Sort By:
Pageof 46
British Journal of Cancer|January 20, 2022
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinomaKyrillus S Shohdy, Dario M Villamar, Yen Cao, et al.British Journal of Cancer|February 20, 2015
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinomaC-F Xu, T Johnson, J Garcia-Donas, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapyK Fizazi, A Ulys, L Sengeløv, et al.Nature Genetics|October 15, 1998
Targeted gene knockout mediated by triple helix forming oligonucleotidesA Majumdar, A Khorlin, N Dyatkina, et al.European Urology|April 21, 2024
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS StudyFred Saad, Maha H A Hussain, Bertrand Tombal, et al.World Journal of Urology|June 26, 2016
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancerM N Pham, A B Apolo, M De Santis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2023
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS TrialMaha Hussain, Bertrand Tombal, Fred Saad, et al.Urologic Oncology|August 22, 2025
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapyC N Sternberg, P Squifflet, E D Saad, et al.The Oncologist|March 5, 2026
Molecular Landscape of Prostate Cancers with Clival MetastasesPornlada Likasitwatanakul, Steven M Blinka, Jabra G Zarka, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trialCora N Sternberg, Daniel P Petrylak, Oliver Sartor, et al.Pageof 46